Peripheral arterial disease and its circulating markers that show reflect the causative factors

A study of endothelial Nitric Oxide Synthase(eNOS), Nitric Oxide (NO), Cytokines, Vascular Endithelial Growth Factors (VEGF)in lower limb arterial disease and their alteration with the clinical outcome

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Observational

Source

CTRI

Registry ID

CTRI/2018/01/011512

Enrollment

150

Registered

2018-01-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- only few healthy volenteers for baseline values (no intervention)

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients with clinical features suggestive of peripheral arterial disease of lower limbs 2.PAD patients with age >18 years

Exclusion criteria

Exclusion criteria: 1.PAD patients with gangrene of foot proximal to toes (fore foot/foot) 2.Recent history of CAD (within 3 months of screening) 3.Patient diagnosed with malignancy in present or past.

Design outcomes

Primary

Measure	Time frame
1.To study the alteration in endothelial Nitric oxide synthase (eNOS), Tumor necrosis factor-alpha (TNF-Î±), Interferon-gamma (IFN-Î³), Interleukin-10, Interleukin-6, Transforming growth factor-beta (TGF-Î²) and VEGF in patients with peripheral arterial disease as compared to controls. 2.To study association between the change levels of biomarkers and progression of the disease. Timepoint: baseline, one month, two month, three months and six months	—

Measure

Time frame

1.To study the alteration in endothelial Nitric oxide synthase (eNOS), Tumor necrosis factor-alpha (TNF-Î±), Interferon-gamma (IFN-Î³), Interleukin-10, Interleukin-6, Transforming growth factor-beta (TGF-Î²) and VEGF in patients with peripheral arterial disease as compared to controls. 2.To study association between the change levels of biomarkers and progression of the disease. Timepoint: baseline, one month, two month, three months and six months

—

Secondary

Measure	Time frame
To study association between the change levels of biomarkers and progression of the disease. Timepoint: Base line, one month two months third month and sixth month after intervention.	—

Countries

India

Contacts

Public ContactDr Anita Dhar

All India Institute of Medical Sciences

dranitadharbhan@gmail.com09810198239

Outcome results